Skip to search formSkip to main contentSkip to account menu

120 ACTUAT Budesonide 0.18 MG/ACTUAT Dry Powder Inhaler [Pulmicort]

Known as: Pulmicort Flexhaler 0.18 MG/ACTUAT (0.16 MG/ACTUAT from the mouthpiece) Dry Powder Inhaler, 120 ACTUAT, Pulmicort Flexhaler 180 MCG/ACTUAT Dry Powder Inhaler, 120 ACTUAT, Pulmicort Flexhaler 180 MCG/INHAL Dry Powder Inhaler, 120 ACTUAT 
National Institutes of Health

Related topics

Related topics

5 relations
60 ACTUAT Budesonide 0.09 MG/ACTUAT Dry Powder Inhaler [Pulmicort]BudesonideDry Powder InhalerLactose

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Effect of Relative Humidity on Bipolar Electrostatic Charge Profiles of dry Powder Aerosols
This work investigated the effect of relative humidity (RH) on bipolar electrostatic charge profiles of dry powder inhaler… 
2017
2017
Fraction of exhaled nitric oxide and soluble receptors for advanced glycation end products are negatively correlated in children with recurrent wheezing.
BACKGROUND The fraction of exhaled nitric oxide (FeNO) and serum levels of the soluble receptor for advanced glycation end… 
2013
2013
Analysis on the therapeutic effect of aerosol inhalation of pulmicort respules and ambroxol for treating chronic obstructive pulmonary disease
Objective To analyze the therapeutic effect of aerosol inhalation of pulmicort respules and ambroxol for treating chronic… 
2008
2008
Asthma control in pediatric patients treated with once-daily or twice-daily nebulized budesonide inhalation suspension (Pulmicort Respules).
Composite end points may represent more meaningful assessments of asthma control compared with traditional discrete measures. The… 
2007
2007
Effect of Pulmicort respule on rehabilitation after functional endoscopic sinus surgery
Objective: To investigate the effect of Pulmicort respule on rehabilitation of patients subjected to functional endoscopic sinus… 
2007
2007
Pulmicort Respules
Budesonide is a white to off-white, tasteless, odorless powder that is practically insoluble in water and in heptane, sparingly… 
2004
2004
Once-daily budesonide inhalation powder (Pulmicort Turbuhaler®) improves health-related quality of life in adults previously receiving inhaled corticosteroids
In the treatment of asthma, the conventional measures used to monitor a patient’s progress and health status do not address the… 
2003
2003
Assessment of adrenal suppression from two new dry powder inhaler formulations of budesonide delivered by Clickhaler compared with the Pulmicort Turbuhaler.
Assessment of adrenal suppression via systemic cortisol levels provides an indirect measure of the lung delivery of inhaled… 
2002
2002
Safety of pulmicort respulesTM (budesonide inhalation suspension) in geriatric patients: Postmarketing surveillance and clinical study data
1998
1998
The Efficacy & Safety of Once Daily Pulmicort Respules™ (Budesonide Nebulizing Suspension; BNS) and Placebo (PBO) in Infants and Young Children with Persistant Asthma † 1948
Introduction: The current inhalation devices used to deliver inhaled glucocorticosteroids (iGCS) are not optimal for use by… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)